Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Micromet receives FDA feedback on blinatumomab registration for R/R ALL

Micromet receives FDA feedback on blinatumomab registration for R/R ALL

Scientisits uncover evidence of powerful new cancer genetic networks

Scientisits uncover evidence of powerful new cancer genetic networks

Manhattan Scientifics' nano-electromagnetic sensing technology can detect MRD in leukemia

Manhattan Scientifics' nano-electromagnetic sensing technology can detect MRD in leukemia

Cylene advances preclinical development of CX-5461 for treatment of cancer

Cylene advances preclinical development of CX-5461 for treatment of cancer

SFDA approves China Medical Technologies' colorectal cancer assay

SFDA approves China Medical Technologies' colorectal cancer assay

Viewpoints: The value of testing for prostate cancer; rewards for transplant donors; Calif.'s medical marijuana problem

Viewpoints: The value of testing for prostate cancer; rewards for transplant donors; Calif.'s medical marijuana problem

PROLOR receives U.S. patent allowance for CTP-modified interferons

PROLOR receives U.S. patent allowance for CTP-modified interferons

VGX International, Inovio partner to co-develop SynCon vaccines for hepatitis B and C infections

VGX International, Inovio partner to co-develop SynCon vaccines for hepatitis B and C infections

Loyola's SSOM receives $100,000 grant for research into pediatric leukemia

Loyola's SSOM receives $100,000 grant for research into pediatric leukemia

Novel drug shows promise for MLL leukemia

Novel drug shows promise for MLL leukemia

EntreMed announces data from ENMD-2076 Phase 2 study in platinum-resistant ovarian cancer

EntreMed announces data from ENMD-2076 Phase 2 study in platinum-resistant ovarian cancer

Potential new drug could treat mixed-lineage leukaemia

Potential new drug could treat mixed-lineage leukaemia

Kimmel Cancer Center at Jefferson celebrates two decades of caring and collaboration to beat cancer

Kimmel Cancer Center at Jefferson celebrates two decades of caring and collaboration to beat cancer

Researchers develop HTGTS to map translocatome in the genome

Researchers develop HTGTS to map translocatome in the genome

Prototype drug shows promise against chronic lymphocytic leukemia

Prototype drug shows promise against chronic lymphocytic leukemia

Close link between SF3B1 mutation and specific feature of myelodysplastic syndromes

Close link between SF3B1 mutation and specific feature of myelodysplastic syndromes

Researchers identify frequent SF3B1 gene mutation in myelodysplasia

Researchers identify frequent SF3B1 gene mutation in myelodysplasia

Asuragen announces data from Signature LTx v2.0 clinical study on leukemia

Asuragen announces data from Signature LTx v2.0 clinical study on leukemia

Scientists identify a way that chemotherapy causes platelet numbers to drop

Scientists identify a way that chemotherapy causes platelet numbers to drop

Long-term results from ARIAD's ponatinib Phase 1 study on CML and Ph+ ALL

Long-term results from ARIAD's ponatinib Phase 1 study on CML and Ph+ ALL

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.